Reported Earlier, FDA Grants J&J Accelerated Approval For Rybrevant Faspro In Advanced Head And Neck Squamous Cell Carcinoma, Based On OrigAMI-4 Phase 1b/2 Trial Showing 42% Overall Response Rate
Accelerated approval based on data demonstrating clinically meaningful efficacy, including a 42 percent overall response rate (95 percent confidence interval, 32–52 percent)1First advancement in the second-line
Johnson and Johnson got fast approval for a new cancer medicine. The drug helped 42 percent of patients with a tough type of head and neck cancer.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.